RICTOR and head and neck squamous cell carcinoma: We observed genomic aberrations in RICTOR and PIK3CA to significantly co‐occur in HNSCC tumors; as patients with PIK3CA aberrations are thought to be optimal candidates for PI3K inhibition therapy, the prevalence of RICTOR amplifications or RNA overexpression in this cohort may have therapeutic implications (Gkountakos et al., 2018).